1650 related articles for article (PubMed ID: 29915603)
1. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
Front Immunol; 2018; 9():1288. PubMed ID: 29915603
[TBL] [Abstract][Full Text] [Related]
2. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment.
Haas L; Obenauf AC
Front Immunol; 2019; 10():2746. PubMed ID: 31849950
[TBL] [Abstract][Full Text] [Related]
3. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
Ostrand-Rosenberg S; Sinha P; Beury DW; Clements VK
Semin Cancer Biol; 2012 Aug; 22(4):275-81. PubMed ID: 22313874
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
Tuettenberg A; Steinbrink K; Schuppan D
Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
[TBL] [Abstract][Full Text] [Related]
6. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
7. Tuning the Tumor Myeloid Microenvironment to Fight Cancer.
Jahchan NS; Mujal AM; Pollack JL; Binnewies M; Sriram V; Reyno L; Krummel MF
Front Immunol; 2019; 10():1611. PubMed ID: 31402908
[TBL] [Abstract][Full Text] [Related]
8. mTOR at the Transmitting and Receiving Ends in Tumor Immunity.
Guri Y; Nordmann TM; Roszik J
Front Immunol; 2018; 9():578. PubMed ID: 29662490
[TBL] [Abstract][Full Text] [Related]
9. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
10. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
Park SY; Kim IS
Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
12. Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.
Abrams SI; Netherby CS; Twum DY; Messmer MN
J Interferon Cytokine Res; 2016 Jul; 36(7):442-53. PubMed ID: 27379866
[TBL] [Abstract][Full Text] [Related]
13. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
[TBL] [Abstract][Full Text] [Related]
14. Interactions among myeloid regulatory cells in cancer.
Umansky V; Adema GJ; Baran J; Brandau S; Van Ginderachter JA; Hu X; Jablonska J; Mojsilovic S; Papadaki HA; Pico de Coaña Y; Santegoets KCM; Santibanez JF; Serre K; Si Y; Sieminska I; Velegraki M; Fridlender ZG
Cancer Immunol Immunother; 2019 Apr; 68(4):645-660. PubMed ID: 30003321
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
Ostrand-Rosenberg S; Fenselau C
J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
18. Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy.
Wennerberg E; Lundqvist A; Mao Y; Mougiakakos D
Front Immunol; 2021; 12():718844. PubMed ID: 34276709
[No Abstract] [Full Text] [Related]
19. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies.
Kelliher MA; Roderick JE
Front Immunol; 2018; 9():1718. PubMed ID: 30967879
[TBL] [Abstract][Full Text] [Related]
20. Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor.
Yan D; Adeshakin AO; Xu M; Afolabi LO; Zhang G; Chen YH; Wan X
Front Immunol; 2019; 10():1399. PubMed ID: 31275326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
